| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E Howanitz, M Pardo, D A Smelson, C Engelhart, N Eisenstein, R G Stern, M F Losoncz. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. The Journal of clinical psychiatry. vol 60. issue 1. 1999-03-15. PMID:10074877. |
therefore, we conducted a 12-week double-blind comparison study to assess the efficacy and tolerability of clozapine and chlorpromazine in a group of elderly inpatients with chronic schizophrenia. |
1999-03-15 |
2023-08-12 |
Not clear |
| P F Buckle. New antipsychotic agents: emerging clinical profiles. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037165. |
clozapine has an established role in treatment-resistant schizophrenia. |
1999-03-02 |
2023-08-12 |
Not clear |
| R W Buckman, R D Mala. Clozapine for refractory schizophrenia: the Illinois experience. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037166. |
clozapine for refractory schizophrenia: the illinois experience. |
1999-03-02 |
2023-08-12 |
Not clear |
| R W Buckman, R D Mala. Clozapine for refractory schizophrenia: the Illinois experience. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037166. |
based upon the illinois department of mental health and developmental disabilities' computerized clinical information system, with its integration of client-specific clinical data, a 5-year retrospective study was designed to determine the clinical effectiveness and economic impact of the use of clozapine for treatment-resistant schizophrenia. |
1999-03-02 |
2023-08-12 |
Not clear |
| W H Rei. New vs. old antipsychotics: the Texas experience. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037167. |
a study was conducted in texas state psychiatric facilities of 299 patients with schizophrenia who were taking clozapine, comparing them with 223 matched controls taking traditional neuroleptics. |
1999-03-02 |
2023-08-12 |
Not clear |
| W H Rei. New vs. old antipsychotics: the Texas experience. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037167. |
in a separate study, clozapine therapy was shown to produce a 5-fold decrease in the rate of suicide among patients with schizophrenia. |
1999-03-02 |
2023-08-12 |
Not clear |
| W H Rei. New vs. old antipsychotics: the Texas experience. The Journal of clinical psychiatry. vol 60 Suppl 1. 1999-03-02. PMID:10037167. |
administration of clozapine appears to lower the overall cost of treating schizophrenia by reducing the costs associated with hospitalizations. |
1999-03-02 |
2023-08-12 |
Not clear |
| R J Wyatt, F Karoum, J Masseran. Effects of antipsychotics, vitamin E, and MK-801 on dopamine dynamics in the rat brain following discontinuation of cocaine. Psychiatry research. vol 80. issue 3. 1999-02-25. PMID:9796937. |
in addition to the potential value these findings have for further understanding cocaine abuse, it is proposed that the alteration in dopamine metabolism produced by cocaine, and the ability of haloperidol, clozapine and vitamin e to decrease cocaine's effects, model some biochemical aspects of schizophrenia. |
1999-02-25 |
2023-08-12 |
rat |
| S Kapur, R B Zipursky, G Remingto. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989565. |
clinical and theoretical implications of 5-ht2 and d2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. |
1999-02-25 |
2023-08-12 |
Not clear |
| A F Breier, A K Malhotra, T P Su, D A Pinals, I Elman, C M Adler, R T Lafargue, A Clifton, D Picka. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989566. |
clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. |
1999-02-25 |
2023-08-12 |
Not clear |
| A F Breier, A K Malhotra, T P Su, D A Pinals, I Elman, C M Adler, R T Lafargue, A Clifton, D Picka. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. The American journal of psychiatry. vol 156. issue 2. 1999-02-25. PMID:9989566. |
clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia. |
1999-02-25 |
2023-08-12 |
Not clear |
| C R Young, M B Bowers, C M Mazur. Management of the adverse effects of clozapine. Schizophrenia bulletin. vol 24. issue 3. 1999-02-22. PMID:9718630. |
clozapine has been found to be superior to traditional neuroleptics in the treatment of refractory schizophrenia and is increasingly being used to treat schizophrenia, affective disorders, some neurological disorders, and aggression. |
1999-02-22 |
2023-08-12 |
Not clear |
| R A Dickson, J T Dalby, R Williams, S J Warde. Hospital days in clozapine-treated patients. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 9. 1999-02-22. PMID:9825168. |
to examine inpatient hospital days used by a group of patients with treatment-resistant schizophrenia for 3 years before and 3 years after clozapine initiation. |
1999-02-22 |
2023-08-12 |
Not clear |
| C Guitton, M Abbar, J M Kinowski, P Chabrand, F Bressoll. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 18. issue 6. 1999-02-18. PMID:9864080. |
multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. |
1999-02-18 |
2023-08-12 |
Not clear |
| C Guitton, M Abbar, J M Kinowski, P Chabrand, F Bressoll. Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. Journal of clinical psychopharmacology. vol 18. issue 6. 1999-02-18. PMID:9864080. |
the pharmacokinetic parameters of clozapine and its two main metabolites, n-desmethylclozapine (norclozapine, active metabolite) and clozapine n-oxide, were evaluated, after oral administration, in 19 patients with chronic schizophrenia. |
1999-02-18 |
2023-08-12 |
Not clear |
| M J Travis, G F Busatto, L S Pilowsky, R Mulligan, P D Acton, S Gacinovic, J Mertens, D Terrière, D C Costa, P J Ell, R W Kerwi. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. The British journal of psychiatry : the journal of mental science. vol 173. 1999-02-09. PMID:9926100. |
5-ht2a receptor blockade in patients with schizophrenia treated with risperidone or clozapine. |
1999-02-09 |
2023-08-12 |
Not clear |
| M L Lee, R A Dickson, M Campbell, J Oliphant, H Gretton, J T Dalb. Clozapine and substance abuse in patients with schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 43. issue 8. 1999-02-08. PMID:9806095. |
clozapine and substance abuse in patients with schizophrenia. |
1999-02-08 |
2023-08-12 |
Not clear |
| D P Bassitt, M R Louzã Net. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European archives of psychiatry and clinical neuroscience. vol 248. issue 4. 1999-02-05. PMID:9810484. |
in an open trial seven patients with schizophrenia and severe td were given clozapine for 6 months. |
1999-02-05 |
2023-08-12 |
Not clear |
| C Fleischhaker, E Schulz, H Remschmid. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. Journal of psychiatric research. vol 32. issue 5. 1999-01-29. PMID:9789212. |
biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. |
1999-01-29 |
2023-08-12 |
human |
| C Fleischhaker, E Schulz, H Remschmid. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia. Journal of psychiatric research. vol 32. issue 5. 1999-01-29. PMID:9789212. |
the purpose of the present study was to assess the relationship between plasma monoamine levels and changes in psychopathology in a sample of children and adolescents with schizophrenia (dsm-iii-r criteria) during conventional neuroleptic therapy and during short-term treatment with clozapine. |
1999-01-29 |
2023-08-12 |
human |